V
Visus Therapeutics
Developing innovative medicines to improve vision for people around the world
About Visus Therapeutics
Visus Therapeutics is a clinical-stage pharmaceutical company that specializes in the development of unique and superior ophthalmic therapies. The company is primarily focused on improving the lives of patients by addressing the loss of near vision associated with presbyopia, a common age-related eye condition. Their lead clinical candidate is BRIMOCHOL™, an eye drop that is currently being evaluated for its effectiveness in treating presbyopia.
Read full description
The company operates in the healthcare and pharmaceutical market, serving a broad range of clients including healthcare providers, patients, and other stakeholders in the healthcare industry. With offices in Seattle and Orange County, Visus Therapeutics is strategically positioned to serve its target market effectively.
Visus Therapeutics' business model revolves around the research, development, and commercialization of innovative ophthalmic therapies. The company generates revenue through the sale of its pharmaceutical products once they have been approved for use in the market. The recent positive topline clinical data from their Phase 3 BRIO-I Trial of BRIMOCHOL PF™ indicates that the company is making significant progress towards commercializing their lead product.
In August 2021, Visus Therapeutics hosted its first Capital Markets Day in New York City, a move that underscores the company's commitment to engaging with investors and the broader financial community.
At a glance
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Seattle, United States
- Employees
- 78
- Open positions
- None listed
- Dealroom signal
- 93.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2024 | $0 | — | Tenpoint Therapeutics | ↗ |
| EARLY VCOther financing | Aug 2021 | $20M | $80M | EQT Life Sciences · Johnson & Johnson Innovation · Sage Partners | — |
Growth signals
Latest recorded traffic for Visus Therapeutics is 720 monthly website visits, down 52% over the last three months. Visus Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
RTW Investments
Johnson & Johnson Innovation- WAWille AG
EQT Life Sciences
Sage Partners
Other known investors1 additional known investor
Tenpoint Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Visus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Visus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.